AstraZeneca PLC
LSE:AZN
AstraZeneca PLC
LSE:AZN
Price:
12 050 GBX
-0.87%
Market Closed
Updated:
May 6, 2024
AstraZeneca PLC
Income from Continuing Operations
|
AstraZeneca PLC
Income from Continuing Operations Peer Comparison
Comparables:
GSK
VRNA
INDV
HIK
DPH
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
AstraZeneca PLC
LSE:AZN
|
Income from Continuing Operations
$6B
|
CAGR 3-Years
24%
|
CAGR 5-Years
24%
|
CAGR 10-Years
9%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Income from Continuing Operations
£5.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-1%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Income from Continuing Operations
-$54.4m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Indivior PLC
LSE:INDV
|
Income from Continuing Operations
-$3m
|
CAGR 3-Years
73%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Income from Continuing Operations
$192m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-1%
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Income from Continuing Operations
-£27.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is AstraZeneca PLC's Income from Continuing Operations?
Income from Continuing Operations
6B
USD
6B
USD
Based on the financial report for Dec 31, 2023, AstraZeneca PLC's Income from Continuing Operations amounts to 6B USD.
What is AstraZeneca PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
9%
9%
Over the last year, the Income from Continuing Operations growth was 81%. The average annual Income from Continuing Operations growth rates for AstraZeneca PLC have been 24% over the past three years , 24% over the past five years , and 9% over the past ten years .
You don't have any saved screeners yet
